BTAIQ — BioXcel Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.53m
- $92.14m
- $0.64m
Brief: BioXcel Therapeutics Announces Database Lock In Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia
U.S. STOCKS ON THE MOVE-Soho House, Cogent Communications, Beyond
U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx
Brief: BioXcel Therapeutics Announces Positive FDA Pre-SNDA Meeting Comments For SNDA Submission For Bxcl501 In Agitation Associated With Bipolar Disorders Or Schizophrenia
BioXcel jumps after positive FDA feedback on Alzheimer's-linked drug application
BioXcel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: BioXcel Therapeutics Q2 Basic EPS USD -2.45 Vs. IBES Estimate USD -1.86
BioXcel Therapeutics Inc expected to post a loss of $1.63 a share - Earnings Preview
Brief: Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi
U.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
U.S. STOCKS ON THE MOVE-NIP Group, Hyatt, BioXcel Therapeutics
BioXcel Therapeutics rises on positive schizophrenia drug trial recommendation
Brief: Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia
Brief: Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement
Brief: BioXcel Therapeutics Q1 Basic EPS USD -1.5
BioXcel Therapeutics Inc expected to post a loss of $6.66 a share - Earnings Preview
Brief: Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through Canaccord - SEC Filing
BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary